CORDLIFE GROUP LIMITED

(Company Registration No.: 200102883E) (Incorporated in the Republic of Singapore) (the "<u>Company</u>")

CLARIFICATION ON BUSINESS TIMES CORPORATE DIGEST SECTION DATED 4 AUGUST 2015

The Board of Directors of the Company (the "**Board**") refers to the report (the "**Report**") in the Corporate Digest section of yesterday's The Business Times relating to receipt of a second offer for certain assets of the Company, namely approximately 7.3 million shares of par value US\$0.0001 per share in China Cord Blood Corporation ("**CCBC**") and the 7% senior unsecured convertible note due 3 October 2017 issued by CCBC (the CCBC shares and the convertible note collectively, the "**Assets**").

As there are a number of revisions to the Report, the Board wishes to clarify the following:

(1) The Board has not received a second offer from Golden Meditech Holdings Limited ("**Golden** <u>Meditech</u>") for the Assets. The conditional purchase agreement dated 8 May 2015 between the Company and Golden Meditech pursuant to which the Company agreed to sell the Assets to Golden Meditech remains in force. The Company will in due course be issuing a circular to shareholders of the Company in relation to this proposed sale.

(2) As set out in the Company's announcement on 7 July 2015, the Board received, and after due consideration, rejected an unsolicited offer from a third party to acquire the Assets. A copy of the Company's announcement on 7 July 2015 is annexed.

(3) As set out in the Company's announcement on 3 August 2015, the Board received a revised offer for the Assets from the same third party. The Board is presently reviewing the revised Offer. A copy of the Company's announcement on 3 August 2015 is annexed.

The Company has informed The Business Times of the errors.

The Board will make appropriate announcements at the relevant time should circumstances merit such announcements.

By Order of the Board **CORDLIFE GROUP LIMITED**

Mr. Yee Pinh Jeremy Director 5 August 2015 ANNEX

CORDLIFE GROUP LIMITED (Company Registration No.: 200102883E) (Incorporated in the Republic of Singapore) (the "<u>Company</u>")

UNSOLICITED OFFER TO ACQUIRE SHARES IN CHINA CORD BLOOD CORPORATION AND 7% SENIOR UNSECURED CONVERTIBLE NOTE DUE 2017

The Board of Directors of the Company (the "**Board**") refers to the Company's announcement on 8 May 2015 on the Company's entry into a conditional purchase agreement dated 8 May 2015 (the "**Agreement**") with Golden Meditech Holdings Limited (the "**Purchaser**"), pursuant to which the Company agreed to sell, and the Purchaser agreed to purchase from the Company, 7,314,015 ordinary shares of par value US\$0.0001 per share in China Cord Blood Corporation ("**CCBC**") and 7% senior unsecured convertible note due 3 October 2017 issued by CCBC to the Company in the principal amount of US\$25 million (the convertible note and the shares collectively, the "**Assets**"). The transaction is subject to the approval of the Company's shareholders at a general meeting to be convened.

The Board wishes to announce that it has received an unsolicited offer from a third party to acquire the Assets (the "**Offer**").

After due and careful consideration, the Board has decided to reject the Offer. In coming to its decision, the Board considered a number of relevant commercial and legal factors, including the fact that the Company had already signed the binding Agreement with the Purchaser, the obligations agreed to be performed by the Company under the Agreement, the terms and conditions of the Offer and the relative timing and completion risks associated with each of the Agreement and the Offer.

Shareholders of the Company are advised to refrain from taking any action in relation to their shares of the Company which may be prejudicial to their interests, and to exercise caution when dealing in the shares of the Company.

By Order of the Board **CORDLIFE GROUP LIMITED**

Mr. Yee Pinh Jeremy Director 7 July 2015

CORDLIFE GROUP LIMITED

(Company Registration No.: 200102883E) (Incorporated in the Republic of Singapore) (the "<u>Company</u>")

UNSOLICITED OFFER TO ACQUIRE SHARES IN CHINA CORD BLOOD CORPORATION AND 7% SENIOR UNSECURED CONVERTIBLE NOTE DUE 2017

The Board of Directors of the Company (the "**Board**") refers to the Company's announcement on 7 July 2015 relating to the receipt of an unsolicited offer (the "**Offer**") from a third party to acquire the 7,314,015 ordinary shares of par value US\$0.0001 per share in China Cord Blood Corporation ("**CCBC**") and the 7% senior unsecured convertible note due 3 October 2017 issued by CCBC to the Company in the principal amount of US\$25 million (the shares and the convertible note collectively, the "**Assets**"), which the Company had agreed to sell to Golden Meditech Holdings Limited (the "**Purchaser**"), pursuant to a conditional purchase agreement dated 8 May 2015 (the "**Agreement**") between the Company and the Purchaser. As announced, the Board had decided to reject the Offer after due and careful consideration.

The Board wishes to announce that the Board has received a second offer for the Assets from the same third party on revised terms (the "**<u>Revised Offer</u>**").

The Board is presently reviewing the Revised Offer.

Shareholders of the Company are advised to exercise caution when dealing in the shares of the Company and refrain from taking any action in relation to their shares of the Company which may be prejudicial to their interests until they have considered the information as set out in a circular to shareholders to be issued by the Company in due course.

The Board will make appropriate announcements at the relevant time should circumstances merit such announcements.

By Order of the Board **CORDLIFE GROUP LIMITED**

Mr. Yee Pinh Jeremy Director 3 August 2015